Moreover, no difference was noted between survival (OS and relapse-free survival) and type of KRAS mutation stratified by condon 12 and 13 in patients with stages II and III colon cancer, which is in agreement with our analyses of patients with metachronous mCRC. Here, KRAS is linked to malignant colon neoplasm.